Welcome to our dedicated page for VARONIS SYSTEMS SEC filings (Ticker: VRNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VARONIS SYSTEMS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VARONIS SYSTEMS's regulatory disclosures and financial reporting.
Varonis Systems (VRNS) furnished an 8-K announcing financial results for the third quarter ended September 30, 2025, via a press release attached as Exhibit 99.1. The company notes the information is furnished and not filed under the Exchange Act, and it is incorporated by reference only if expressly stated in a future filing.
Guy Melamed, identified as CFO and COO of Varonis Systems, Inc. (VRNS), reported two sales of common stock under a Rule 10b5-1 trading plan. On 08/28/2025 he sold 3,892 shares at a weighted average price of $59.52, leaving him with 413,605 shares. On 08/29/2025 he sold 1,500 shares at a weighted average price of $59.59, leaving 412,105 shares beneficially owned.
The filing states the trades were executed pursuant to a 10b5-1 plan adopted in 2024 and discloses weighted average price ranges for the transactions. The form is signed by an attorney-in-fact on behalf of the reporting person.
Varonis Systems, Inc. filed a current report to share that it issued a press release announcing the Company’s acquisition of SlashNext, Inc. on September 2, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into the Regulation FD disclosure section of the report. The company notes that this information is being furnished, not filed, so it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities filings unless specifically referenced.
Guy Melamed, Chief Financial Officer and Chief Operating Officer of Varonis Systems, Inc. (VRNS), reported the sale of 10,400 shares of Varonis common stock on 08/22/2025. The shares were sold under a Rule 10b5-1 trading plan adopted in 2024 at a weighted-average price of $59.53 per share, with transaction prices ranging from $59.50 to $59.57. After the sale, Melamed beneficially owned 417,497 shares. The Form 4 was submitted and signed by an attorney-in-fact on 08/26/2025. The filer notes willingness to provide detailed per-price sale data upon request.
Varonis Systems, Inc. (VRNS) notice reports a proposed sale of 100,000 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $5,852,000 and 112,047,109 shares outstanding. The securities were acquired as restricted stock units on 02/29/2024 and payment/settlement is recorded as N/A. The filer reports no sales in the past three months and includes a representation about absence of undisclosed material adverse information.
Notice of Proposed Sale under Rule 144: This Form 144 reports a proposed sale of 56,940 common shares of Varonis Systems, Inc. (VRNS) with an aggregate market value of $3,332,128.80, using Morgan Stanley Smith Barney LLC as broker and an approximate sale date of 08/22/2025. The shares were acquired as Performance Stock Units on 02/29/2024. The filing shows 112,047,109 shares outstanding. The record also lists two 10b5-1 sales by Guy Melamed within the past three months: 42,705 shares sold on 08/13/2025 for $2,465,133.31 and 51,889 shares sold on 08/01/2025 for $2,859,281.08. The filer attests to Rule 10b5-1 representations and confirms no undisclosed material adverse information.
Insider sale by Varonis CFO/COO under 10b5-1 plan. Guy Melamed, who serves as Chief Financial Officer and Chief Operating Officer, reported a sale of 42,705 shares of Varonis Systems, Inc. (VRNS) on 08/13/2025 at a weighted average price of $57.72 per share. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted in 2024. After this transaction, Melamed beneficially owned 427,897 shares. The Form 4 was signed by an attorney-in-fact on behalf of Melamed and was filed as an individual report.
Varonis Systems filed a Form 144 notifying a proposed sale of 42,705 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $2,427,352.20. The filing lists 112,047,109 shares outstanding and an approximate sale date of 08/13/2025.
The securities were acquired as Restricted Stock Units on 02/29/2024. The notice also records a prior 10b5-1 sale for Guy Melamed of 51,889 shares on 08/01/2025 with gross proceeds of $2,859,281.08. The filing includes the standard seller representation regarding undisclosed material information and references Rule 10b5-1 plan considerations.
Varonis Systems (VRNS) Form 4 – Insider Transaction
Chief Financial & Operating Officer Guy Melamed sold 51,889 common shares on 08/01/2025 under a pre-arranged Rule 10b5-1 plan. The shares were disposed at a weighted-average price of $55.10 (range $55.01–$55.24), generating proceeds of roughly $2.9 million. Following the sale, Melamed’s direct ownership stands at 470,602 shares.
No derivative securities were involved and no acquisitions were reported. The filing signals a reduction of approximately 10% of Melamed’s prior direct stake, yet he retains a sizeable position. Because the transaction was executed through a 10b5-1 program, it was scheduled in advance and may not reflect current views on VRNS valuation.